Dentsply Sirona Q2 revenue slightly beats estimates
XRAY•Drivers and segment performance
The company said results reflect progress on distributor relationships, sales team realignment, and reinvestment as part of its Return-to-Growth Action Plan.
Revenue declined in most segments, with Orthodontic and Implant Solutions down 13.2% year over year, while Wellspect Healthcare grew 7.1%.
Analyst expectations and valuation
The current average analyst rating on the shares is hold, with 3 strong buy or buy, 12 hold and 2 sell or strong sell recommendations.
The median 12-month price target for DENTSPLY SIRONA Inc. is $14.00, about 1.6% above its August 5 closing price of $13.78. The stock recently traded at 9 times the next 12-month earnings, versus 8 times three months ago.
Quarterly results slightly beat revenue estimates
Dentsply Sirona's second-quarter revenue declined 4.1% year over year, but slightly beat analyst expectations. Adjusted EPS for the quarter was flat at $0.52 year over year.
The company repurchased 1.3 million shares during the quarter.
